Browsing by Author "Sumbul, A. T."

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    The Analysis of Lncrna HOTAIR Rs12826786 C > T Polymorphism and Gastric Cancer Susceptibility in A Turkish Population: Lack of Any Association in A Hospital-Based Case-Control Study
    (2017) Ulger, Y.; Dadas, E.; Kaya, B. Yalinbas; Sumbul, A. T.; Genc, A.; Bayram, S.; https://orcid.org/0000-0002-5573-906X; 28342055; D-4793-2014
    The HOX transcript antisense intergenic RNA (HOTAIR), a well-known long noncoding RNA (lncRNA), has been widely identified to participate in pathogenesis of multiple cancers. An aberrant up-regulation and biological functions have been observed in gastric cancer (GC). A common single nucleotide polymorphism (SNP) (rs12826786 C > T) at the HOTAIR has been reported to influence HOTAIR expression, but its association with GC has yet to be investigated in Turkish population. The aim of the present study was to investigate whether HOTAIR rs12826786 C > T polymorphism could be involved in the risk of GC susceptibility in Turkish population. We genotyped HOTAIR rs12826786 C > T polymorphism in 312 Turkish individuals including 105 GC patients and 207 healthy controls matched on age and gender by a Real-Time Polymerase Chain Reaction (PCR) with the TaqMan assay. No statistically significant differences were found in the allele or genotype distributions of the HOTAIR rs12826786 C > T polymorphism among GC and healthy control subjects (P > 0.05). Our results demonstrate that the HOTAIR rs12826786 C > T polymorphism has not been in any major role in genetic susceptibility to gastric carcinogenesis, at least in the population studied here. Independent studies are needed to validate our findings in a larger series, as well as in patients of different ethnic origins.
  • No Thumbnail Available
    Item
    Clinicohistopathological Features and Treatment Outcomes of Neuroendocrine Tumors; A Single Center Experience
    (2017) Sumbul, A. T.; Sedef, A. M.; Kose, F.; Mertsoylu, H.; Sezer, A.; Ozyilkan, O.; Abali, H.; https://orcid.org/0000-0002-5573-906X; https://orcid.org/0000-0001-8825-4918; D-4793-2014; AAD-2817-2021
  • No Thumbnail Available
    Item
    Pertuzumab, Trastuzumab and Taxane Combination for Visceral Organ Metastatic Patients: Real Life Practice Results
    (2018) Esin, E.; Oksuzoglu, O. B. Cakmak; Bilici, A.; Cicin, I.; Aksoy, S.; Alacacioglu, A.; Kaplan, M. A.; Cabuk, D.; Sumbul, A. T.; Paydas, S.; Sakin, A.; Er, O.; Korkmaz, T.; Yildirim, N.; Artac, M.; Harputluoglu, H.; Yumuk, P. F.; Basaran, G.; Uluc, B. Oyan; Demirci, U.; 0000-0002-5573-906X; D-4793-2014
  • No Thumbnail Available
    Item
    Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes
    (2019) Sumbul, A. T.; 30377778; D-4793-2014
    PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.